<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Ocular</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Sun Pharma to acquire Merck spinoff Organon for $11.75B</title>
      <description>
        <![CDATA[Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730787</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730787-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Three-red-darts-on-target.webp?t=1761844421" type="image/jpeg" medium="image" fileSize="465362">
        <media:title type="plain">Three red darts on target</media:title>
      </media:content>
    </item>
    <item>
      <title>Sun Pharma to acquire Merck spinoff Organon for $11.75B</title>
      <description>
        <![CDATA[Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730643</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730643-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Three-red-darts-on-target.webp?t=1761844421" type="image/jpeg" medium="image" fileSize="465362">
        <media:title type="plain">Three red darts on target</media:title>
      </media:content>
    </item>
    <item>
      <title>Forsight’s robot-assisted platform to transform cataract surgery</title>
      <description>
        <![CDATA[The first fully robot-assisted cataract surgery recently performed using Forsight Robotics Ltd.’s Jasper platform was not only a “transformative” event and a major “milestone” for the company, but also a “huge step forward for the industry,” Joseph Nathan, co-founder, president and chief medical officer, told <em>BioWorld</em>. With one in two people globally needing cataract surgery and unable to get access to care, robot-assisted platforms hold the potential to increase surgical throughput and broaden access to treatment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730602</guid>
      <pubDate>Thu, 23 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730602-forsights-robot-assisted-platform-to-transform-cataract-surgery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Joseph-Nathan-co-founder-president-and-chief-medical-officer-Forsight-Robotics-4-23.webp?t=1776975792" type="image/jpeg" medium="image" fileSize="413486">
        <media:title type="plain">Joseph Nathan, co-founder, president, and chief medical officer, Forsight Robotics</media:title>
        <media:description type="plain">Joseph Nathan, co-founder, president and chief medical officer, Forsight Robotics</media:description>
      </media:content>
    </item>
    <item>
      <title>Revenio speeds up growth acquiring Visionix for €290M</title>
      <description>
        <![CDATA[Revenio Group Oyj has agreed to acquire ophthalmic diagnostics company Visionix International SAS for an enterprise value of €290 million (US$339 million) as it looks to become a leading player in the global eye care market. The deal expands Revenio’s offering with a highly complementary product and software portfolio, including optical coherence tomography equipment, an important and growing segment which is new to the company.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730279</guid>
      <pubDate>Mon, 13 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730279-revenio-speeds-up-growth-acquiring-visionix-for-290m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Close-up-of-eye-and-vision-test.webp?t=1730493501" type="image/jpeg" medium="image" fileSize="159676">
        <media:title type="plain">Close up of eye and vision test</media:title>
      </media:content>
    </item>
    <item>
      <title>AXL inhibition as therapeutic approach for retinoblastoma</title>
      <description>
        <![CDATA[Researchers from Sun Yat-sen University and collaborators reported the preclinical efficacy of SGI-7079, an AXL inhibitor, in models of retinoblastoma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730329</guid>
      <pubDate>Mon, 13 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730329-axl-inhibition-as-therapeutic-approach-for-retinoblastoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-tumor-blood-supply-vessels.webp?t=1683902294" type="image/jpeg" medium="image" fileSize="254242">
        <media:title type="plain">Art concept for tumor</media:title>
      </media:content>
    </item>
    <item>
      <title>With $80M series D, Life Biosciences advances epigenetic reprogramming  </title>
      <description>
        <![CDATA[Armed with a fully subscribed $80 million series D round, Life Biosciences Inc. is making progress with its lead candidate, ER-100, which is in phase I trials testing its theory on reversing the biological effects of aging via partial epigenetic reprogramming.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730208</guid>
      <pubDate>Thu, 09 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730208-with-80m-series-d-life-biosciences-advances-epigenetic-reprogramming</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-mutation-variation.webp?t=1722524925" type="image/jpeg" medium="image" fileSize="179355">
        <media:title type="plain">Illustration of double helix </media:title>
      </media:content>
    </item>
    <item>
      <title>Smart contact lens delivers adaptative glaucoma therapy</title>
      <description>
        <![CDATA[A smart polymer contact lens measures intraocular pressure (IOP) in real time and automatically releases medication into the eye when IOP goes beyond a critical limit. This technological advance, developed by scientists at the Terasaki Institute for Biomedical Innovation (TIBI), could enable personalized glaucoma therapy, avoiding poor patient adherence to their prescribed regimen and eliminating the need for bulky electronic devices. Animal models tolerate it well and, although the load is concentrated at the edges of the lens, it is still unknown how it could affect visual acuity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730276</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730276-smart-contact-lens-delivers-adaptative-glaucoma-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-anatomy-and-contact-lens.webp?t=1775678594" type="image/jpeg" medium="image" fileSize="480794">
        <media:title type="plain">Eye anatomy and contact lens</media:title>
      </media:content>
    </item>
    <item>
      <title>Merck Wnt first, Surrozen goes next in AMD, DME </title>
      <description>
        <![CDATA[As advances are made by bustling drug developers at work in the Wingless-related integration site (Wnt) pathway, other research is yielding new discoveries as well. Among the closely watched industry players in Wnt are Boehringer Ingelheim GmbH, Merck & Co. Inc., and Surrozen Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730150</guid>
      <pubDate>Wed, 08 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730150-merck-wnt-first-surrozen-goes-next-in-amd-dme</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Illustration-of-Wnt-signaling-pathway.webp?t=1741386502" type="image/jpeg" medium="image" fileSize="376774">
        <media:title type="plain">Illustration of Wnt signaling pathway</media:title>
      </media:content>
    </item>
    <item>
      <title>Smart contact lens delivers adaptative glaucoma therapy</title>
      <description>
        <![CDATA[A smart polymer contact lens measures intraocular pressure (IOP) in real time and automatically releases medication into the eye when IOP goes beyond a critical limit. This technological advance, developed by scientists at the Terasaki Institute for Biomedical Innovation, could enable personalized glaucoma therapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730149</guid>
      <pubDate>Wed, 08 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730149-smart-contact-lens-delivers-adaptative-glaucoma-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-anatomy-and-contact-lens.webp?t=1775678594" type="image/jpeg" medium="image" fileSize="480794">
        <media:title type="plain">Eye anatomy and contact lens</media:title>
      </media:content>
    </item>
    <item>
      <title>Khartis Therapeutics identifies new IGF-1R inhibitors</title>
      <description>
        <![CDATA[Work at Khartis Therapeutics Inc. has led to the discovery of new insulin-like growth factor 1 receptor (IGF-1R; CD221) inhibitors potentially useful for the treatment of thyroid-associated ophthalmopathy (Graves ophthalmopathy), age-related macular degeneration, idiopathic orbital inflammatory disease, cancer and inflammatory disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730198</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730198-khartis-therapeutics-identifies-new-igf-1r-inhibitors</link>
    </item>
    <item>
      <title>LHON updates: Gene therapy progress; idebenone receives US CRL </title>
      <description>
        <![CDATA[Chiesi Group’s idebenone faced a regulatory setback last month after the U.S. FDA issued a complete response letter (CRL) to the company’s NDA for Leber hereditary optic neuropathy (LHON), a rare inherited disorder that causes sudden vision loss.But a chance missed for Chiesi may be an opportunity for gene therapies, including Gensight Biologics SA’s lenadogene nolparvovec (Lumevoq; GS-010).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730074</guid>
      <pubDate>Thu, 02 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730074-lhon-updates-gene-therapy-progress-idebenone-receives-us-crl</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eya-and-DNA-illustration.webp?t=1658513444" type="image/png" medium="image" fileSize="350713">
        <media:title type="plain">Eye and DNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovent’s IBI-302 meets phase III endpoints in neovascular AMD </title>
      <description>
        <![CDATA[Innovent Biologics Inc.’s efdamrofusp alfa (IBI-302) met the primary endpoint in the phase III Star trial in neovascular age-related macular degeneration (nAMD), and the Suzhou, China-based company will submit an NDA to China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730089</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730089-innovents-ibi-302-meets-phase-iii-endpoints-in-neovascular-amd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Amsler-grid-test.webp?t=1627064994" type="image/png" medium="image" fileSize="427571">
        <media:title type="plain">Woman taking Amsler grid eye exam</media:title>
      </media:content>
    </item>
    <item>
      <title>Highly complementary Biogen pays $5.6B; who’s jealous of Apellis? </title>
      <description>
        <![CDATA[Biogen Inc. hardly blinked at the competition faced by Apellis Pharmaceuticals Inc. as the two companies sealed a deal whereby the former has agreed to acquire all outstanding shares of the latter for $41 each, or about $5.6 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729963</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729963-highly-complementary-biogen-pays-56b-whos-jealous-of-apellis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Handshake-with-charts-maps-data.webp?t=1701801114" type="image/jpeg" medium="image" fileSize="281005">
        <media:title type="plain">Handshake with charts, maps, data</media:title>
      </media:content>
    </item>
    <item>
      <title>Elegrobart star in TED phase III but Viridian shares sacked</title>
      <description>
        <![CDATA[Analysts were sounding pleased and the company intends to go ahead with a regulatory filing, but investors seem to have wanted more from Viridian Therapeutics Inc.’s top-line data from the elegrobart (formerly VRDN-003) Reveal-1 phase III trial in active thyroid eye disease (TED). Viridian shares (NASDAQ:VRDN) closed March 30 at $18.53, down $8.86, or 32%.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729946</guid>
      <pubDate>Mon, 30 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729946-elegrobart-star-in-ted-phase-iii-but-viridian-shares-sacked</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Ocular-eye1.webp?t=1589292057" type="image/png" medium="image" fileSize="296406">
        <media:title type="plain">Face with digital focus on eye</media:title>
      </media:content>
    </item>
    <item>
      <title>Kodiak’s Zenkuda sparkles in Glow2, BLA filing next</title>
      <description>
        <![CDATA[After previous setbacks with the program, investors largely brushed aside ocular-focused Kodiak Sciences Inc.’s anticipated phase III Glow2 data of tarcocimab tedromer in diabetic retinopathy (DR), so the positive top-line superiority results revealed March 26 caught many by surprise as it sets the company up for an accelerated multi-indication BLA submission.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729899</guid>
      <pubDate>Thu, 26 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729899-kodiaks-zenkuda-sparkles-in-glow2-bla-filing-next</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-wireframe-illustration.webp?t=1688152353" type="image/jpeg" medium="image" fileSize="165854">
        <media:title type="plain">Eye wireframe illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovent’s IBI-302 meets phase III endpoints in neovascular AMD </title>
      <description>
        <![CDATA[Innovent Biologics Inc.’s efdamrofusp alfa (IBI-302) met the primary endpoint in the phase III Star trial in neovascular age-related macular degeneration (nAMD), and the Suzhou, China-based company will submit an NDA to China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729841</guid>
      <pubDate>Wed, 25 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729841-innovents-ibi-302-meets-phase-iii-endpoints-in-neovascular-amd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Amsler-grid-test.webp?t=1627064994" type="image/png" medium="image" fileSize="427571">
        <media:title type="plain">Woman taking Amsler grid eye exam</media:title>
      </media:content>
    </item>
    <item>
      <title>Aldeyra collects third CRL for reproxalap in dry eye disease</title>
      <description>
        <![CDATA[It’s déjà vu all over again for Aldeyra Therapeutics Inc., which disclosed its third complete response letter (CRL) for dry eye disease candidate reproxalap, with the U.S. FDA citing a lack of substantial and consistent evidence of efficacy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729718</guid>
      <pubDate>Tue, 17 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729718-aldeyra-collects-third-crl-for-reproxalap-in-dry-eye-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Ocular-eye-analysis.webp?t=1682529922" type="image/png" medium="image" fileSize="566355">
        <media:title type="plain">Close up of man's eye</media:title>
      </media:content>
    </item>
    <item>
      <title>P2X7 receptor antagonists detailed in Breye Therapeutics patent</title>
      <description>
        <![CDATA[Breye Therapeutics Aps has reported P2X purinoceptor 7 (P2RX7; P2X7) antagonists potentially useful for the treatment of age-related macular degeneration (AMD), cardiovascular, cognitive, eating disorder, headache, liver diseases, neurodegeneration and neuroinflammation, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729683</guid>
      <pubDate>Tue, 17 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729683-p2x7-receptor-antagonists-detailed-in-breye-therapeutics-patent</link>
    </item>
    <item>
      <title>Resident macrophages reveal the immune side of glaucoma</title>
      <description>
        <![CDATA[Scientists at Duke University have uncovered how macrophages help maintain intraocular pressure and have found that a specific type, resident macrophages, is essential for proper drainage of intraocular fluid. When these cells are removed, drainage becomes impaired and intraocular pressure rises, contributing to the development of glaucoma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729662</guid>
      <pubDate>Thu, 12 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729662-resident-macrophages-reveal-the-immune-side-of-glaucoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Aqueous-humor-drainage-from-the-eye.webp?t=1773240930" type="image/jpeg" medium="image" fileSize="611343">
        <media:title type="plain">Illustration showing aqueous humor drainage from the eye</media:title>
        <media:description type="plain">Aqueous humor drainage from the eye regulates intraocular pressure. It passes through the trabeculum and Schlemm’s canal, preventing glaucoma.</media:description>
      </media:content>
    </item>
    <item>
      <title>Three pediatric brain cancer types share a pineal gland origin</title>
      <description>
        <![CDATA[Similarities among three pediatric brain tumors that arise in different structures of the CNS – pineoblastoma, retinoblastoma and Group 3 medulloblastoma – have been linked to their shared origin during pineal gland development. Scientists at St. Jude Children’s Research Hospital have identified the molecular signatures that drive these tumors from pinealocyte progenitor cells that conserve a common differentiation program, providing a shared therapeutic target for these three cancer types.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729642</guid>
      <pubDate>Wed, 11 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729642-three-pediatric-brain-cancer-types-share-a-pineal-gland-origin</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-Pineal-gland.webp?t=1773154224" type="image/jpeg" medium="image" fileSize="214692">
        <media:title type="plain">Illustration of brain cross-section showing the pineal gland</media:title>
      </media:content>
    </item>
    <item>
      <title>Resident macrophages reveal the immune side of glaucoma</title>
      <description>
        <![CDATA[Scientists at Duke University have uncovered how macrophages help maintain intraocular pressure and have found that a specific type, resident macrophages, is essential for proper drainage of intraocular fluid. When these cells are removed, drainage becomes impaired and intraocular pressure rises, contributing to the development of glaucoma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729587</guid>
      <pubDate>Wed, 11 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729587-resident-macrophages-reveal-the-immune-side-of-glaucoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Aqueous-humor-drainage-from-the-eye.webp?t=1773240930" type="image/jpeg" medium="image" fileSize="611343">
        <media:title type="plain">Illustration showing aqueous humor drainage from the eye</media:title>
        <media:description type="plain">Aqueous humor drainage from the eye regulates intraocular pressure. It passes through the trabeculum and Schlemm’s canal, preventing glaucoma.</media:description>
      </media:content>
    </item>
    <item>
      <title>Roche identifies new soluble epoxide hydrolase inhibitors</title>
      <description>
        <![CDATA[F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized pyridone carboxamide-derived compounds acting as soluble epoxide hydrolase inhibitors. They are reported to be useful for the treatment of diabetic retinopathy, neuropathic pain and neurodegenerative diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729522</guid>
      <pubDate>Tue, 10 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729522-roche-identifies-new-soluble-epoxide-hydrolase-inhibitors</link>
    </item>
    <item>
      <title>Three pediatric brain cancer types share a pineal gland origin</title>
      <description>
        <![CDATA[Similarities among three pediatric brain tumors that arise in different structures of the CNS – pineoblastoma, retinoblastoma and Group 3 medulloblastoma – have been linked to their shared origin during pineal gland development. Scientists at St. Jude Children’s Research Hospital have identified the molecular signatures that drive these tumors from pinealocyte progenitor cells that conserve a common differentiation program, providing a shared therapeutic target for these three cancer types.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729507</guid>
      <pubDate>Tue, 10 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729507-three-pediatric-brain-cancer-types-share-a-pineal-gland-origin</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-Pineal-gland.webp?t=1773154224" type="image/jpeg" medium="image" fileSize="214692">
        <media:title type="plain">Illustration of brain cross-section showing the pineal gland</media:title>
      </media:content>
    </item>
    <item>
      <title>EB-203 improves diabetic retinopathy-like pathology in zebrafish</title>
      <description>
        <![CDATA[In a recent publication in <em>Biomedicine & Pharmacotherapy</em>, investigators evaluated the activity of a 7-amino-acid peptide, EB-203, using a zebrafish model of diabetic retinopathy (DR)-like vascular alterations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729419</guid>
      <pubDate>Mon, 09 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729419-eb-203-improves-diabetic-retinopathy-like-pathology-in-zebrafish</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Ocular-eye-diabetic-retinopathy-illustration.webp?t=1773070137" type="image/jpeg" medium="image" fileSize="149131">
        <media:title type="plain">Illustration showing cross section of eye with diabetic retinopathy</media:title>
      </media:content>
    </item>
    <item>
      <title>GWAS identifies variant associated with diabetic retinopathy and susceptibility to T2D</title>
      <description>
        <![CDATA[Scientists at the University of Nottingham Ningbo China and collaborators aimed to identify genetic variants associated with diabetic retinopathy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729391</guid>
      <pubDate>Fri, 06 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729391-gwas-identifies-variant-associated-with-diabetic-retinopathy-and-susceptibility-to-t2d</link>
    </item>
    <item>
      <title>Sanaregen Vision’s SVT-001 cleared for clinic for familial drusen</title>
      <description>
        <![CDATA[Sanaregen Vision Therapeutics Inc. has received FDA clearance to conduct a phase I/II trial of SVT-001, an investigational cell therapy for individuals with familial drusen.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729151</guid>
      <pubDate>Tue, 03 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729151-sanaregen-visions-svt-001-cleared-for-clinic-for-familial-drusen</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-macula-diagram.webp?t=1713453488" type="image/jpeg" medium="image" fileSize="294587">
        <media:title type="plain">Medical vector illustration showing cross section of an eyeball with close up of the macula</media:title>
      </media:content>
    </item>
    <item>
      <title>New mouse model of Sjögren’s disease-associated dry eye</title>
      <description>
        <![CDATA[Scientists based at Capital Medical University (Beijing, China) have designed a lacrimal gland-specific autoimmune model that recapitulates the main features of Sjögren’s disease-associated dry eye.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728970</guid>
      <pubDate>Mon, 23 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728970-new-mouse-model-of-sjogrens-disease-associated-dry-eye</link>
    </item>
    <item>
      <title>Subretinal NRF2 gene therapy preserves retinal function in dry AMD models</title>
      <description>
        <![CDATA[Researchers from Harvard Medical School and Spark Therapeutics Inc. tested subretinal NRF2 gene therapy in dry AMD models to investigate whether it could relieve oxidative stress and inflammation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728955</guid>
      <pubDate>Fri, 20 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728955-subretinal-nrf2-gene-therapy-preserves-retinal-function-in-dry-amd-models</link>
    </item>
    <item>
      <title>Financing at Gelmedix supports GMX-101 for geographic atrophy</title>
      <description>
        <![CDATA[Gelmedix Inc. has completed a $13 million seed financing to support progression of the company’s lead program, GMX-101, a retinal pigment epithelial (RPE) cell therapy to treat late-stage geographic atrophy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728920</guid>
      <pubDate>Wed, 18 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728920-financing-at-gelmedix-supports-gmx-101-for-geographic-atrophy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RD-money.webp?t=1588877677" type="image/png" medium="image" fileSize="578436">
        <media:title type="plain">Dollar sign droplet above test tube</media:title>
      </media:content>
    </item>
    <item>
      <title>Eylea threatened Inlyta Ocular’s phase III win with Axpaxli?</title>
      <description>
        <![CDATA[Ocular Therapeutix Inc.’s wet age-macular degeneration candidate, Axpaxli, beat anti-VEGF therapy Eylea (aflibercept) from Regeneron Pharmaceuticals Inc. in the phase III head-to-head trial called Sol-1, but not by enough of a margin for Wall Street. Shares of the firm (NASDAQ:OCUL) closed Feb. 17 at $6.99, down $1.89, or 21%, as investors mulled the top-line findings.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728992</guid>
      <pubDate>Tue, 17 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728992-eylea-threatened-inlyta-oculars-phase-iii-win-with-axpaxli</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/eye-analysis.webp?t=1589292229" type="image/png" medium="image" fileSize="545833">
        <media:title type="plain">Close-up of eye with digital focus</media:title>
      </media:content>
    </item>
  </channel>
</rss>
